Maureen Sanderson1,2, Loren Lipworth3,4,5, Jaleesa Moore6, Tuya Pal7,1, Alicia Beeghly-Fadiel6,1, Mary Kay Fadden2, Heather M Munro8, Steffie-Ann Dujon2, Sonya Reid1,9, Ann Tezak7,1, Miaya Blasingame10, Jeania Ware11, William J Blot6,1, Xiao-Ou Shu6,1, Wei Zheng6,1. 1. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA. 3. Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. loren.lipworth@vumc.org. 4. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. loren.lipworth@vumc.org. 5. Vanderbilt Epidemiology Center, 2525 West End Avenue, Suite 300, Nashville, TN, 37203-1738, USA. loren.lipworth@vumc.org. 6. Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 7. Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. 8. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA. 9. Division of Hematology/Oncology, Department of Medicine, Breast Cancer Program, Vanderbilt University Medical Center, Nashville, TN, USA. 10. Vanderbilt University School of Medicine, Nashville, TN, USA. 11. Meharry Medical College, Nashville, TN, USA.
Abstract
PURPOSE: To evaluate the association between obesity and the relative prevalence of tumor subtypes among Black women with breast cancer (BC). METHODS: We conducted a pooled case-only analysis of 1,793 Black women with invasive BC recruited through three existing studies in the southeastern US. Multivariable case-only polytomous logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between obesity, measured by pre-diagnostic body mass index (BMI), and human epidermal growth factor receptor 2 + (HER2 +) and triple negative BC (TNBC) subtype relative to hormone receptor (HR) + /HER2- status (referent). RESULTS: Among 359 premenopausal women, 55.4% of cases were HR + /HER2 -, 20.1% were HER2 + , and 24.5% were TNBC; corresponding percentages among 1,434 postmenopausal women were 59.3%, 17.0%, and 23.6%. Approximately, 50-60% of both pre- and postmenopausal women were obese (BMI > 30 kg/m2), regardless of BC subtype. We did not observe a significant association between obesity and BC subtype. Among postmenopausal women, class I obesity (BMI 35 + kg/m2) was not associated with the development of HER2 + BC (OR 0.69; 95% CI 0.42-1.14) or TNBC (OR 0.93; 95% CI 0.60-1.45) relative to HR + /HER2- tumors. Corresponding estimates among premenopausal women were 1.03 (95% CI 0.43-2.48) and 1.13 (95% CI 0.48-2.64). CONCLUSION: In this large study of Black women with BC, there was no evidence of heterogeneity of BMI by BC subtype.
PURPOSE: To evaluate the association between obesity and the relative prevalence of tumor subtypes among Black women with breast cancer (BC). METHODS: We conducted a pooled case-only analysis of 1,793 Black women with invasive BC recruited through three existing studies in the southeastern US. Multivariable case-only polytomous logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between obesity, measured by pre-diagnostic body mass index (BMI), and human epidermal growth factor receptor 2 + (HER2 +) and triple negative BC (TNBC) subtype relative to hormone receptor (HR) + /HER2- status (referent). RESULTS: Among 359 premenopausal women, 55.4% of cases were HR + /HER2 -, 20.1% were HER2 + , and 24.5% were TNBC; corresponding percentages among 1,434 postmenopausal women were 59.3%, 17.0%, and 23.6%. Approximately, 50-60% of both pre- and postmenopausal women were obese (BMI > 30 kg/m2), regardless of BC subtype. We did not observe a significant association between obesity and BC subtype. Among postmenopausal women, class I obesity (BMI 35 + kg/m2) was not associated with the development of HER2 + BC (OR 0.69; 95% CI 0.42-1.14) or TNBC (OR 0.93; 95% CI 0.60-1.45) relative to HR + /HER2- tumors. Corresponding estimates among premenopausal women were 1.03 (95% CI 0.43-2.48) and 1.13 (95% CI 0.48-2.64). CONCLUSION: In this large study of Black women with BC, there was no evidence of heterogeneity of BMI by BC subtype.
Authors: Lisa B Signorello; Margaret K Hargreaves; Mark D Steinwandel; Wei Zheng; Qiuyin Cai; David G Schlundt; Maciej S Buchowski; Carolyne W Arnold; Joseph K McLaughlin; William J Blot Journal: J Natl Med Assoc Date: 2005-07 Impact factor: 1.798
Authors: Sherene Loi; Roger L Milne; Michael L Friedlander; Margaret R E McCredie; Graham G Giles; John L Hopper; Kelly-Anne Phillips Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-07 Impact factor: 4.254